<DOC>
	<DOCNO>NCT01085552</DOCNO>
	<brief_summary>A study see single subcutaneous dose Epoetin beta ( NeoRecormon® ) healthy Japanese compare single subcutaneous dose Epoetin beta ( NeoRecormon® ) Caucasian Male subject . Each subject receive single subcutaneous dose 50IU/kg NeoRecormon Multidose solution Day 1 .</brief_summary>
	<brief_title>Bioequivalence Single Subcutaneous Dose Epoetin Beta Healthy Japanese Caucasian Male Subjects</brief_title>
	<detailed_description>Ethnic comparison study become common research requirement order identify difference response drug various ethnic population . This study investigate pharmacokinetic parameter pharmacodynamic response healthy Caucasian Japanese male subject single subcutaneous administration 50IU/kg Epoetin beta This Phase I single centre , open label trial investigate bioequivalence single subcutaneous dose Epoetin beta ( NeoRecormon® ) healthy Japanese Caucasian Male subject . The primary objective 1 ) establish pharmacokinetic parameter Epoetin beta healthy Japanese Caucasian male , 2 ) compare pharmacokinetic parameter AUCinf Cmax healthy Japanese Caucasian male . The secondary objective establish pharmacodynamic parameter single dose Epoetin beta healthy Japanese Caucasian male . Subjects receive single subcutaneous administration 50IU/kg one occasion . The plan study duration approximately 1 month .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Healthy male Japanese volunteer ( parent four grandparent must Japanese , subject must bear Japan , subject usually reside Japan resident outside Japan 5 year ) , Healthy male Caucasian volunteer . Aged 20 40 year age . Body weight 50kg 80 kg inclusive Body mass index ( BMI ) 18 29 kg/m2 inclusive screening . Subjects must good health determine medical history , medical examination , electrocardiogram , serum biochemistry , haematology , serology urinalysis . Provide write informed consent participate trial read information consent form , opportunity discuss trial investigator delegate . Sufficient intelligence understand nature trial hazard participate . Ability communicate satisfactorily investigator and/or delegate participate , comply requirement 's entire trial . Willing abstain Alcohol consumption 48 hour trial drug administration last outpatient visit . Subjects must willing use one follow method contraception first dose trial medication completion followup procedure : In addition use condom spermicide ( foam/gel/film ) , male subject without vasectomy must assure female partner use another form contraception IUD , diaphragm hormonal contraception female partner could become pregnant time first dose trial medication one month follow visit . Have upper limit of14g/dL haemoglobin , 45 % Hematocrit 1.9 % Reticulocytes . Have normal safety result Creatinine , Liver function test , serum Ferritin , Folic acid vitamin B12 screen assessment Clinically relevant abnormal history , physical finding , ECG , laboratory value screen visit could interfere objective trial safety volunteer . Clinically significant illness within 4 week prior screen visit . Subjects past present history liver disease , angina , renal disease , hypertension , epilepsy , cardiovascular , cerebrovascular , thrombocytosis peripheral vascular disease . Subjects use systemic , topical prescription , nonprescription herbal medication within 14 day start dose exception paracetamol 3g per day . Subjects smoke 5 cigarette per day . Subjects donate 400ml blood 1 month dosing . Subjects received investigational product 3 month precede trial . Subjects clinically significant history drug hypersensitivity allergic disease . Subjects consume 28 unit alcohol per week history alcoholism evidence drug/chemical abuse . ( one unit alcohol equal ½ pint [ 285 ml ] beer lager , one glass [ 125 ml ] wine l [ 25ml ] spirit ) Subjects consume excessive amount caffeine ( 5 cup equivalent per day . Subjects positive urine drug screen screen visit admission . Subjects know history evidence hepatitis B , hepatitis C HIV1 HIV2 . Subjects opinion GP investigator participate study . Possibility subject cooperate requirement protocol set volunteer information . Subjects previous exposure erythropoietin</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>NeoRecormon®</keyword>
	<keyword>Caucasian</keyword>
	<keyword>Japanese</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Ethnic</keyword>
</DOC>